RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS INFECTIONS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New mRNA vaccine targets RSV in first human trial
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests an experimental mRNA vaccine designed to protect against respiratory syncytial virus (RSV). Around 213 healthy adults aged 18-45 will receive different doses of the vaccine or a placebo. The main goal is to check for side effects and measure the immun…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated May 01, 2026 16:00 UTC
-
New mRNA vaccine aims to shield against RSV
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests a new mRNA vaccine called IN006 that targets respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive one of three doses or a placebo. Researchers will monitor side effects and measure the body's immune response to se…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE1 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 29, 2026 15:02 UTC